Ha Kung WongPartner, New York
Professional Experience
Ha Kung Wong practices general intellectual property law with an emphasis on complex patent and trade secret litigation in pharmaceuticals, biologics and chemistry. Cases Mr. Wong has litigated include those related to proton pump inhibitors, anti-epileptic drugs, anti-tussives and other pharmaceuticals. Mr. Wong also has extensive experience with intellectual property counseling, pre-suit investigations, licensing and due diligence.
Mr. Wong currently is the Chair of the Recruiting Committee, serves as faculty for NITA (the National Institute of Trial Advocacy) and Lawline, and has been named a "Furthered 40" by Lawline for his contributions.
Awards and Recognition
Ha Kung Wong is listed in Legal 500 2008 and 2009 for Patent litigation: full coverage. Mr. Wong is also listed as a Rising Star in Intellectual Property Litigation in the 2012 issue of Super Lawyers: New York Metro Edition.
For information on the selection process, see:
Legal 500
Super Lawyers
Education
J.D., cum laude, Notre Dame Law School, 1999
B.S., Chemistry, High Distinction, B.S. Biochemistry, University of Illinois Urbana-Champaign, 1996
Bar Admissions
State of New York, 2000; U.S. District Courts for the Southern and Eastern Districts of New York, 2001
Professional Activities
American Bar Association; New York Bar Association; New York Patent Law Association; American Chemical Society; New York Intellectual Property Law Association
Additional Publications
While in law school, Mr. Wong served as Managing Editor for the Journal of Legislation and published, "The Extra in Extradition: Washington v. Pang's Impact on Extraditee Standing and Implicit Waiver," 24 J.Legis 111 (1998).
Representative Matters
- AstraZeneca against Andrx, Genpharm, Dr. Reddy and Schwartz Pharma on patents relating to omeprazole and its formulations.
- Bristol-Myers Squibb against The Regents of the University of Michigan and Repligen Corp. and ZymoGenetics on patents relating to synthetic fusion proteins for regulating the immune system.
- UCB against Mylan, Dr. Reddy, Sandoz and Cobalt on patents relating to levetiracetam, a leading epilepsy medicine.
- GlaxoSmithKline against Barr Pharmaceuticals on patents relating to dutasteride, a leading BPH drug.
- UCB and Celltech against KV Pharmaceutical on patents relating to methylphenidate hydrochloride, an ADHD medicine.
Representative Cases
-
UCB Societe Anonyme & UCB Pharma Inc. v. Mylan Laboratories, Inc. et al.
N.D. GA 2006 -
In re Omeprazole Patent Litigation
S.D.N.Y. 2002
-
A Shifting Landscape in Patent False Marking: Effects of Recent Legal Changes
Financier Worldwide Magazine
October 2012 -
Strategic Patent Protection in the “New World” after the America Invents Act
China Intellectual Property Magazine
September 10, 2012 -
AIA & Paragraph IV Litigation: What’s Next?
LMG Life Sciences
May 2012 -
Conducting an IP Audit When Laws Change
New York Law Journal
May 9, 2012 -
Trade Secret Law Reform: Could an Amended Economic Espionage Act Overcome Inconsistencies in the Current State Law System?
Bloomberg Law Reports: Intellectual Property
January 2012 -
Preparing for Uncertainties in Biosimilars Litigation
Financier Worldwide
January 2011 -
Recent legislation impacts development of biologics
Financier Worldwide
November 2010 -
Obvious to Try? The Slippery Slope of Biotechnology
Bloomberg Law Reports Intellectual Property
May 10, 2010 -
Combine and conquer: handling biotech combination inventions in the wake of KSR
Nature Biotech
May 2009
PUBLICATIONS
-
America Invents Act: The Significant Changes for Patent Prosecutors and Litigators
Lawline.com
October 21, 2011 -
21st Forum on Biotech Patenting
C5
October 5-6, 2011 -
2nd Annual Conference on Biosimilars
American Conference Institute
Fitzpatrick partners Raymond Mandra and Ha Kung Wong spoke at ACI's 2nd Annual Conference on Biosimilars
June 7-8, 2011 -
3rd Annual Pre-Litigation Strategy, Analysis and Preparation for Paragraph IV Disputes
The Center for Business Intelligence
October 18- 19, 2010 -
Assessing Small Molecule IP: Exclusivities & the Hatch-Waxman Act
lawline.com
September 15, 2010 -
5th Annual Pharmaceutical & Biotech Patent Litigation Strategies Conference
IQPC
Partners Scott K. Reed and Ha Kung Wong to speak at Biotech Conference in London
May 24-26th, 2010 -
Highlighting In-Depth Interference Practices, Patent Life Cycle Management and Litigation Tactics
IQPC's 2nd Annual Patent Strategies for the Pharma, Biotech and Medical Device Industries
July 15-16, 2008
EVENTS
-
Twelve Fitzpatrick Partners Named As Top New York Intellectual Property Litigators
Super Lawyers: New York Metro Edition
September 2012
IN THE NEWS
-
New Partners named in January 2008
January 2, 2008
PRESS RELEASES
- E hwong@fchs.com
- T (212) 218-2571
- F (212) 218-2200
- Outlook vCard
- E-mail this page
- Print PDF (Short Bio)
